Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - WhiteFiber, Inc. (WYFI) is up 21% at $17.35 [3] - Rising Dragon Acquisition Corp. (RDAC) is up 21% at $12.63 [3] - Julong Holding Limited (JLHL) is up 13% at $3.45 [3] - Linkhome Holdings Inc. (LHAI) is up 11% at $12.50 [3] - A SPAC III Acquisition Corp. (ASPC) is up 9% at $13.09 [3] - Intuitive Machines, Inc. (LUNR) is up 7% at $11.61 [3] - Ascent Solar Technologies, Inc. (ASTI) is up 7% at $3.31 [3] - Bitmine Immersion Technologies, Inc. (BMNR) is up 6% at $30.39 [3] - Velo3D, Inc. (VELO) is up 5% at $12.10 [3] - Gain Therapeutics, Inc. (GANX) is up 4% at $2.36 [3] Premarket Losers - cbdMD, Inc. (YCBD) is down 17% at $1.60 [4] - Mega Fortune Company Limited (MGRT) is down 16% at $7.33 [4] - Cassava Sciences, Inc. (SAVA) is down 14% at $2.43 [4] - NIKE, Inc. (NKE) is down 10% at $59.01 [4] - InMed Pharmaceuticals Inc. (INM) is down 6% at $1.21 [4] - Datacentrex, Inc. (DTCX) is down 5% at $3.23 [4] - Abundia Global Impact Group Inc (AGIG) is down 5% at $1.50 [4] - PSQ Holdings, Inc. (PSQH) is down 5% at $1.00 [4] - Paranovus Entertainment Technology Ltd. (PAVS) is down 4% at $2.34 [4] - Worksport Ltd. (WKSP) is down 4% at $2.09 [4]

Group 1 - InMed Pharmaceuticals held its 2025 Annual General Meeting of Shareholders, chaired by CEO Eric Adams [1][2] - The meeting included a sworn declaration confirming that all materials were mailed to security holders as of October 22, 2025 [3]

Core Insights - NVIDIA Corp reported third-quarter revenue of $57.0 billion, a 62% increase year-over-year, surpassing the consensus estimate of $54.88 billion, leading to a 5.2% rise in pre-market trading [1] Company Performance - NVIDIA's strong financial results and positive revenue forecast contributed to a significant increase in its stock price [1] - Sonder Holdings Inc experienced a dramatic 138.8% surge to $0.22 in pre-market trading despite filing for Chapter 7 bankruptcy [5] - Inspire Veterinary Partners Inc gained 60.3% to $0.17 after a previous decline of 61% [5] - PACS Group Inc rose 39.7% to $23.49 following better-than-expected third-quarter sales results [5] - Cerence Inc surged 29.2% to $10.23 after reporting strong fourth-quarter results and issuing optimistic first-quarter sales guidance [5] - InMed Pharmaceuticals Inc increased by 24.3% to $1.53 after successful pharmacokinetic studies for its Alzheimer's candidate [5] - Oddity Tech Ltd gained 20.1% to $44.62 after reporting better-than-expected third-quarter results and raising FY25 guidance [5] - Kulicke And Soffa Industries Inc rose 16.2% to $41.01 after reporting strong fourth-quarter results and optimistic first-quarter guidance [5] Stock Movements - WeShop Holdings Limited tumbled 38.8% to $122.33 after a significant previous jump [5] - Brera Holdings PLC declined 35.5% to $3.73 following a 13% drop [5] - Meihua International Medical Tech Co Ltd fell 23.8% to $0.18 after announcing a 1-for-100 reverse stock split [5] - JX Luxventure Group Inc dipped 13.8% to $0.39 after a previous decline [5] - Vizsla Silver Corp fell 12.6% to $4.08 after announcing a $250 million convertible senior notes offering [5] - Palo Alto Networks Inc fell 4.6% to $190.90 despite reporting upbeat first-quarter results and raising fiscal 2026 guidance [5]

Core Viewpoint - InMed Pharmaceuticals will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York, where the management team will conduct one-on-one meetings with investors and present updates on their drug development pipeline [1][2]. Group 1: Company Overview - InMed Pharmaceuticals is focused on developing proprietary small molecule drug candidates targeting diseases with high unmet medical needs, including Alzheimer's, ocular, and dermatological conditions [3]. - The company's leading pharmaceutical program, INM-901, is aimed at treating Alzheimer's disease and has recently presented data at the Alzheimer's Association International Conference (AAIC) 2025 [2][3]. Group 2: Conference Details - The H.C. Wainwright 27th Annual Global Investment Conference will feature a corporate presentation from InMed, which will be available online for 90 days [3]. - The conference provides an opportunity for InMed's management to engage directly with investors through one-on-one meetings [1].

Core Insights - InMed Pharmaceuticals is presenting new preclinical data on its drug candidate INM-901 at the Alzheimer's Association International Conference (AAIC) 2025, focusing on its potential in treating Alzheimer's disease [1][5]. Group 1: Study Findings - The study evaluates INM-901 using a long-term 5xFAD mouse model, showing improvements in cognitive function, anxiety-related behavior, and sensory responsiveness [3]. - Treatment with INM-901 resulted in a significant reduction in inflammatory biomarkers, indicating a dose-dependent therapeutic effect in neuroinflammation [6]. - Behavioral improvements were observed, with cognitive function and anxiety-related behavior approaching normal levels following treatment with INM-901 [12]. Group 2: Mechanisms of Action - INM-901 targets multiple biological pathways associated with Alzheimer's disease, demonstrating anti-inflammatory action and neuroprotection by significantly reducing amyloid-beta-induced cell death [12]. - The drug promotes neurite outgrowth, enhancing neuronal connectivity and function, which aligns with observed improvements in cognition and memory [12]. - Molecular validation through mRNA data supports the behavioral findings, indicating a comprehensive therapeutic potential for INM-901 in Alzheimer's pathology [12]. Group 3: Conference Details - The AAIC 2025 will take place from July 27-31, 2025, in Toronto, Canada, serving as a premier global event for advancing research in dementia and cognitive health [5][8].

Core Points - InMed Pharmaceuticals has appointed CBIZ as its new auditor following the resignation of Marcum LLP due to CBIZ's acquisition of Marcum's attest business, effective June 12, 2025 [1][2] - The resignation of Marcum was not due to any disagreements regarding InMed's financial statements, and previous audit reports did not contain adverse opinions [2] - A special meeting of shareholders was held but no business was conducted due to lack of quorum, resulting in no vote on the proposed issuance of 20% or more of the Company's common shares [3] - InMed has amended its Standby Equity Purchase Agreement (SEPA) with Yorkville, allowing for a temporary suspension of the use of its existing registration statement during a "Black Out Period" [4][5] - During any Black Out Period, Yorkville is prohibited from selling shares under the registration statement, but may sell through other legal exemptions [5][6] Company Overview - InMed Pharmaceuticals focuses on developing proprietary small molecule drug candidates targeting diseases with high unmet medical needs, including Alzheimer's and dermatological conditions [8]